Drugs in ATC Class L01EF

Up to Top Level ATC Classes

Up to L - Antineoplastic and immunomodulating agents

Up to L01 - ANTINEOPLASTIC AGENTS

Up to L01E - PROTEIN KINASE INHIBITORS

Drugs in ATC Class: L01EF - Cyclin-dependent kinase (CDK) inhibitors

Tradename	Generic Name
IBRANCE	palbociclib
KISQALI	ribociclib succinate
KISQALI FEMARA CO-PACK (COPACKAGED)	letrozole; ribociclib succinate
PALBOCICLIB	palbociclib
VERZENIO	abemaciclib

L01EF Market Analysis and Financial Projection

The ATC class L01EF, encompassing Cyclin-dependent kinase (CDK) inhibitors, represents a rapidly evolving segment in oncology therapeutics, driven by robust market growth and a dynamic patent landscape.

Market Dynamics

The global CDK inhibitors market is projected to expand from $9.27 billion in 2024 to $13.45 billion by 2034, reflecting a 5.6% CAGR [2][7]. Key drivers include:

• Rising cancer incidence, particularly hormone receptor-positive breast cancer, where CDK4/6 inhibitors like Palbociclib (L01EF01), Ribociclib (L01EF02), and Abemaciclib (L01EF03) are frontline treatments[6][7].
• Increased R&D investment and advancements in personalized medicine, enabling targeted therapies[2][7].
• Combination therapies, such as CDK4/6 inhibitors paired with hormone therapies, which enhance efficacy and address resistance[4][13].

Emerging trends include next-generation CDK inhibitors targeting CDK7 and CDK9 for broader oncology applications. For instance, Syros Pharmaceuticals’ CDK7 inhibitor (US20240034742A1) and Prelude Therapeutics’ heterocycle-based compounds (US20230265083A1) highlight innovation beyond CDK4/6[5][11].

Patent Landscape

The patent ecosystem for CDK inhibitors is highly competitive, characterized by:

1. Structural Innovations: Modifications to core pharmacophores, such as Novartis’ LEE-011 (Ribociclib) and Pfizer’s Palbociclib, which share pyrimidine-based scaffolds but differ in substituents to optimize selectivity[4].
2. Expanding Targets: Patents now cover CDK2, CDK7, and CDK9 inhibitors, addressing resistance mechanisms and diverse cancer types. Origenis GmbH’s pyrazolotriazine derivatives (CDK2/9) and Syros’ CDK7-focused therapies exemplify this trend[8][11].
3. Combination Strategies: Over 25% of recent patents emphasize combinations with agents like Bcl-2 or BET inhibitors to overcome therapeutic resistance[11][13].

Competitive Outlook

• Dominant Players: Pfizer (Palbociclib), Novartis (Ribociclib), and Eli Lilly (Abemaciclib) lead the market, supported by established clinical efficacy[4][6].
• Emerging Biotechs: Companies like Prelude Therapeutics and Syros Pharmaceuticals are advancing novel inhibitors, often through partnerships to accelerate development[5][11].
• Geographic Trends: North America holds the largest market share (40%), while Asia-Pacific shows the highest growth potential due to rising healthcare investments[7][15].

Challenges and Opportunities

• Regulatory Hurdles: High development costs and stringent approval processes remain barriers[7].
• White Spaces: Patent landscape analyses identify opportunities in CDK7/9 inhibition and drug delivery systems, with 15% of recent filings focused on nanoparticle formulations[14].

Key Takeaways

• CDK inhibitors are pivotal in oncology, with a market trajectory fueled by innovation and unmet clinical needs.
• The patent landscape underscores a shift toward multitargeted therapies and combination regimens to enhance durability.
• Strategic collaborations and biomarker-driven R&D will likely define the next wave of CDK inhibitors, aligning with precision medicine trends[2][13].

“The structural similarities [between CDK4/6 inhibitors] make their analogous CDKs inhibition profiles... quite obvious.” — PMC (2018)[4]

References

1. https://www.kegg.jp/entry/D10652
2. https://www.openpr.com/news/3875304/leading-element-driving-change-in-the-cancer-cdk-inhibitors
3. https://patents.google.com/patent/US20120100100A1/en
4. https://pmc.ncbi.nlm.nih.gov/articles/PMC6271685/
5. https://www.pharmaceutical-technology.com/data-insights/prelude-therapeutics-files-patent-for-heterocycle-cdk-inhibitors-and-their-pharmaceutical-compositions/
6. https://atcddd.fhi.no/atc_ddd_index/?code=L01EF&showdescription=no
7. https://www.forinsightsconsultancy.com/reports/cancer-cdk-inhibitors-market/
8. https://www.bioworld.com/articles/698046-new-cdk-inhibitors-described-in-origenis-patent
9. https://www.globenewswire.com/news-release/2025/03/14/3043095/0/en/Comprehensive-Near-Infrared-Spectroscopy-Patent-Landscape-Report-Reveals-Market-to-Reach-USD-989-8-Million-by-2032.html
10. https://www.marketsandmarkets.com/Market-Reports/air-traffic-control-equipment-market-159216929.html
11. https://www.pharmaceutical-technology.com/data-insights/syros-pharmaceuticals-files-patent-for-treating-cancer-with-compound-of-formula-i/
12. https://straitsresearch.com/report/luxury-pen-market
13. https://www.prnewswire.com/news-releases/cdk-7-inhibitors-market-is-expected-to-showcase-a-significant-growth-by-2034--delveinsight-302258094.html
14. https://yjtrivedi.com/patent-landscape-analysis-a-run-through/
15. https://www.alliedmarketresearch.com/air-traffic-control-equipment-market